Search Results
Your search for The ,The matches 34595 pages
Showing 151 - 200
Case 1: Resected EGFR-Mutant NSCLC
This is Part 1 of EGFR-Mutant NSCLC: Treatment Considerations for Early-Stage Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Stephen Liu, Tina Cascone, and Susan Scott discuss the treatment of resected EGFR-mutant...
Confronting the Growing Global Threat of Antimicrobial Resistance in Cancer Care
The dire warnings about the lethal consequences of unchecked antimicrobial resistance are getting louder and becoming more urgent. The U.S. Department of Health and Human Services has called antimicrobial resistance “one of the most important health security threats of our time,” with at least 2.8...
New Guideline Supports Transoral Robotic Surgery in the Multidisciplinary Management of Patients With Oropharyngeal Cancer
Transoral robotic surgery (TORS) can offer patients with oropharyngeal squamous cell carcinoma (OPSCC) improved survival while minimizing or avoiding late toxicities associated with the standard of care of radiation with cisplatin chemotherapy, according to a recent ASCO guideline.1 “We show in a...
New ASCO Guideline Addresses Germline and Somatic Genomic Testing in Metastatic Prostate Cancer
Prostate carcinoma is the most common type of cancer among men in the United States, accounting for more than 299,000 estimated new cases and approximately 35,000 new deaths in 2024.1 A new ASCO guideline based on findings from a systematic review indicates that in metastatic cases of prostate...
Early Research Evaluates Association Between Diet and Lung Cancer Risk
The long-term impact of diet on health has been well studied, leading to guidance about limiting the consumption of red meat, alcohol, and other foods associated with an increased risk of malignancies such as colorectal, breast, and liver cancers. Researchers at the University of Florida Health...
inMIND Trial: Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma
The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology...
High Levels of PTSD May Exist Among Caregivers of Adult Patients With Cancer
Investigators looked into the toll that caregiving for adult patients with cancer may take on the mental health of caregivers, according to a recent study published by Klekovkina et al in Archives of Gerontology and Geriatrics Plus. Background Millions of family members and friends provide care for ...
Colorectal Cancer May Be Linked to Heightened Risk of Cardiovascular Mortality
The risk of death from cardiovascular causes may be higher among patients diagnosed with colorectal cancer compared with the general population, according to new findings presented by Ayaz et al at the American College of Cardiology (ACC) Annual Scientific Session 2025. Background Cardiovascular...
Can Adding Antihistamines to Second-Line Therapy Improve Outcomes in Advanced Urothelial Carcinoma?
As reported in the journal Urologic Oncology: Seminars and Original Investigations by Fallara et al, an analysis of individual patient data from the IMvigor210 and IMvigor211 trials revealed that concomitant second-line treatment of locally advanced or metastatic urothelial carcinoma with...
Advanced Refractory Melanoma: Addition of Tilsotolimod to Ipilimumab
As reported in the Journal of Clinical Oncology by Adi Diab, MD, and colleagues, the phase III ILLUMINATE trial showed adding the Toll-like receptor-9 agonist tilsotolimod to ipilimumab in patients with advanced refractory melanoma produced no benefit. Study Details Four hundred and eighty-one...
Benefit of Regular Physical Activity Prior to Cancer Diagnosis
Regular physical activity prior to a cancer diagnosis may be linked to a lower risk of disease progression and mortality, according to a recent study conducted by Professor Jon S. Patricios, MBBCh, of the University of Witwatersrand, Johannesburg, South Africa, and colleagues and published in the...
Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma
Neoadjuvant therapy that combines chemotherapy, radiotherapy, and the investigational PD-1 inhibitor sintilimab led to a significantly higher pathologic complete response rate in patients with locally advanced esophageal squamous cell carcinoma, according to data presented at the 2025 ASCO...
Douglas Hanahan, PhD, FAACR, to Be Honored at 2025 AACR Annual Meeting
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Douglas Hanahan, PhD, FAACR, during the upcoming 2025 AACR Annual Meeting, to be held April 25–30 at the McCormick Place Convention...
Monica M. Bertagnolli, MD, FACS, FASCO, Joins Friends of Cancer Research Board of Directors
Friends of Cancer Research (Friends) is honored to announce the addition of former Director of the National Institutes of Health (NIH) Monica M. Bertagnolli, MD, FACS, FASCO, to its Board of Directors. “Dr. Bertagnolli has built her incredible career around improving the lives of patients through...
Recent FDA Approvals in Lymphoma and in Rarer Tumors
The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adults with relapsed or refractory large B-cell lymphoma (LBCL)—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising ...
Advancing Clinical Decisions With Circulting Tumor DNA: Insights From Recent Clinical Trials
Circulating tumor DNA (ctDNA) has evolved from an experimental biomarker to an increasingly actionable tool, informing treatment decisions throughout colorectal cancer care. Whether guiding adjuvant therapy intensification or de-escalation, refining organ-preservation strategies in rectal cancer,...
Intraperitoneal Paclitaxel Combination Regimen Improves Overall Survival in Advanced Gastric Cancer
Adding intraperitoneal (IP) paclitaxel to standard intravenous (IV) paclitaxel plus S-1 (oral fluoropyrimidine derivative) significantly extended overall survival for patients with gastric cancer peritoneal metastases, according to data presented at the 2025 ASCO Gastrointestinal Cancers...
Exploratory Post Hoc Analysis of DUO-E Reveals Olaparib’s Benefit in Endometrial Cancer Subsets
The phase III DUO-E study evaluated the addition of the monoclonal antibody durvalumab to chemotherapy, and the benefit of maintenance durvalumab, with and without the PARP inhibitor olaparib, in advanced endometrial cancer. As reported this past year,1 the inclusion of durvalumab reduced the risk...
Misconceptions Regarding Skin Cancer Risk in the United States
Investigators may have uncovered associations between the reported number of sunburns and sociodemographic characteristics as well as the prevalence of protective skin behaviors adopted by U.S. adults, according to a recent study published by Etzel et al in the American Journal of Lifestyle...
AI Tool May Help to Predict Which Patients With Prostate Cancer May Benefit From Focal Therapy
A novel artificial intelligence (AI) tool, called Unfold AI, may help to determine which men with prostate cancer are most likely to benefit from partial gland cryoablation, according to a recent study published by Brisbane et al in BJUI Compass. The findings may play a key role in improving...
Advanced PD-L1–Positive NSCLC: Ivonescimab vs Pembrolizumab
In an interim analysis of a Chinese phase III trial (HARMONi) reported in The Lancet, Xiong et al found that ivonescimab—a bispecific antibody against PD-1 and VEGF—significantly improved progression-free survival vs pembrolizumab in the first-line setting for patients with advanced PD-L1–positive...
FDA Approves Pembrolizumab for HER2-Positive Gastric or GEJ Cancer Expressing PD-L1
The U.S. Food and Drug Administration (FDA) has granted traditional approval to the PD-L1 inhibitor pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic...
Techniques for Preventing Taxane-Induced Neuropathy in Breast Cancer
In a German single-center trial (POLAR) reported in JAMA Oncology, Michel et al found that hand cooling and hand compression were associated with a reduced risk of taxane-induced neuropathy in women with primary breast cancer. Study Details In the trial, 101 patients enrolled at the National Center ...
Definitive Radiation Therapy Effectively Treats Locally Advanced BCC
Definitive radiation therapy offers a high degree of locoregional control in large, locally advanced basal cell carcinomas (BCC), according to results from a recent multi-institutional research study published by Su et al in the International Journal of Radiation Oncology · Biology · Physics. One...
Checking PSA Levels Too Soon After Prostatectomy May Lead to Overtreatment, Says Study
In a paper published in JAMA Oncology, Tilki et al reported that the current standard monitoring of prostate-specific antigen (PSA) following radical prostatectomy—1.5 to 2 months—is too short to accurately identify recurrence and inform treatment decisions. Rather, PSA levels should be measured...
Triple-Negative Breast Cancer: Neoadjuvant Nivolumab Initiation
In the phase II Neo-N trial reported in The Lancet Oncology, Zdenkowski et al found no apparent advantage of lead-in nivolumab in neoadjuvant therapy comprised of nivolumab/carboplatin/paclitaxel for patients with early triple-negative breast cancer. Study Details In the investigator-initiated,...
Is Active Monitoring a Safe Option for Patients With Ductal Carcinoma In Situ?
With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which patients, however, might safely forgo the current recommendations and be safely followed with active...
Exercise Intervention May Improve Sexual Dysfunction in Men With Prostate Cancer
Erectile dysfunction could be improved through regular exercise in men with prostate cancer, according to a recent study published by Galvão et al in JAMA Network Open. Background Sexual dysfunction is a critical adverse effect of prostate cancer treatment and a major survivorship issue among...
Race-Associated Molecular Differences and Treatment Response in Pancreatic Cancer
Investigators studied race-associated molecular differences in the pancreatic tumors of Black and White patients to determine whether such differences were associated with response to immunotherapy. The findings were published recently by Mandal et al in Cancer Research Communications and reinforce ...
Case 3: Second-Line Therapy for HR-Positive/HER2-Positive Metastatic Breast Cancer
This is Part 3 of Evolving Paradigms in the Treatment of HR-Positive/HER2-Positive Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Sara Tolaney, Ian Krop, and Mark Pegram discuss second-line therapy...
Case 2: Next Steps After First-Line Induction Therapy for HR-Positive/HER2-Positive Metastatic Breast Cancer
This is Part 2 of Evolving Paradigms in the Treatment of HR-Positive/HER2-Positive Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Sara Tolaney, Ian Krop, and Mark Pegram discuss how to manage a...
Case 1: De Novo Metastatic HR-Positive/HER2-Positive Breast Cancer
This is Part 1 of Evolving Paradigms in the Treatment of HR-Positive/HER2-Positive Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Sara Tolaney, Ian Krop, and Mark Pegram discuss the treatment of de...
In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers
The 2025 ASCO Gastrointestinal Cancers Symposium once again delivered a slate of high-impact studies spanning esophageal, gastric, hepatocellular, pancreatic, biliary tract, and colorectal malignancies. Experts in the field offered fresh perspectives on evolving standards of care, and investigators ...
The Real Cost Campaign May Have Prevented Thousands of Youths From Initiating E-Cigarette Use
The U.S. Food and Drug Administration’s (FDA) youth e-cigarette prevention campaign, known as The Real Cost, may have successfully reduced e-cigarette use among youth, according to a recent study published by MacMonegle et al in the American Journal of Preventive Medicine. Background The Real Cost...
Receipt of Guideline-Concordant Care in Patients With Inflammatory Breast Cancer
Investigators may have uncovered the proportion of patients with inflammatory breast cancer who receive guideline-concordant care, according to a recent study published by Tadros et al in JAMA Network Open. Background Clinical practice guidelines currently recommend neoadjuvant systemic therapy...
High-Risk Rhabdomyosarcoma: Long-Term Outcomes With Maintenance Chemotherapy
As reported in the Journal of Clinical Oncology by Gianni Bisogno, MD, PhD, and colleagues, long-term follow-up of the European Paediatric Soft Tissue Sarcoma Study Group RMS2005 trial showed significant survival advantages with the use of maintenance chemotherapy in pediatric patients with...
Cervical Cancer Outcomes According to Urban vs Rural Residence
In a study reported as a research letter in JAMA Network Open, Amboree et al found that women with cervical cancer living in rural U.S. counties had poorer outcomes than those living in urban counties. Study Details The trial used data from the National Program of Cancer Registries and...
Radiotherapy Alone Following Radical Hysterectomy for Cervical Cancer: Should It Remain the Standard of Care?
Results from the phase III NRG Oncology GOG-0263 trial—which tested the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma—indicated that the addition of...
Do Congenital Heart Defects Affect Cancer Risk in Newborns and Their Mothers?
Newborns with congenital heart defects may have a higher risk of developing childhood cancer compared to children born without a heart abnormality. Further, congenital heart defects in newborns may also signal an elevated cancer risk for their mothers. These findings were published recently by Huh...
MRD and Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA NSCLC
The ADAURA trial findings showed a significant benefit in disease-free survival with the EGFR inhibitor osimertinib, compared to placebo, making it the recommended standard of adjuvant treatment in patients with EGFR-mutated non–small cell lung cancer (NSCLC) for up to 3 years after surgery. In a...
BVAC-C Plus Durvalumab May Show Potential in Patients With Recurrent Cervical Cancer
A novel treatment approach may improve outcomes in patients with recurrent or metastatic cervical cancer, according to new findings presented by Choi et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer. Recurrent cervical cancer remains a significant challenge,...
Advances in Endometrial Cancer Detection, Treatment
Two novel studies may provide insights into advancements in the detection and treatment of endometrial cancer, according to new findings presented by Moore et al and Nolin et al at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer. Together, the two studies...
Atezolizumab Plus Carboplatin/Paclitaxel in Advanced Thymic Carcinoma
In a Japanese phase II trial (MARBLE) reported in The Lancet Oncology, Shukuya et al found that atezolizumab plus carboplatin/paclitaxel showed promising results in patients with recurrent or metastatic thymic carcinoma. Study Details In the multicenter trial, 48 patients enrolled between June 2022 ...
Pembrolizumab and Bevacizumab in Untreated Melanoma Brain Metastases
In a phase II trial reported in Journal of Clinical Oncology, Weiss et al found that the combination of pembrolizumab and bevacizumab was active in patients with previously untreated melanoma brain metastases. Study Details In the trial, 37 patients, enrolled at Yale Cancer Center and Moffitt...
Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD
Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual disease (MRD) after induction therapy, according to data presented during the 2024 American Society ...
Neoadjuvant Combination Immunotherapy for Head and Neck Cancer
A combination of two immunotherapies may improve treatment response among patients with head and neck squamous cell carcinomas compared with just one immunotherapy drug, according to a recent study published by Li et al in Cancer Cell. Background Head and neck squamous cell carcinomas occur in the...
Genomic Study Reveals Similarities, Differences in Ovarian Cancer Mutations Among Black, White Patients
Investigators may have uncovered nearly identical mutations to previously examined patient populations and several notable differences that may be clinically relevant among Black patients with ovarian cancer, according to a recent study published by Lawson-Michod et al in Cancer Research....
Enfortumab Vedotin Plus Pembrolizumab Continues to Show Benefit in Metastatic Urothelial Carcinoma
In previously untreated patients with locally advanced or metastatic urothelial carcinoma, use of the antibody-drug conjugate enfortumab vedotin-ejfv in combination with the PD-1 inhibitor pembrolizumab continues to demonstrate a significant survival benefit over chemotherapy, according to updated...
Cervical Precancer Incidence Decreases as HPV Vaccination Rates Rise
Recent findings from the Human Papillomavirus (HPV) Vaccine Impact Monitoring Project (HPV-IMPACT), which were published by Gargano et al in the Morbidity and Mortality Weekly Report, revealed decreased incidences of cervical intraepithelial neoplasia (CIN)2+ and CIN3+ lesions among young women....
Combination Therapy Could Help Overcome Drug Resistance in Patients With KRAS-Mutated NSCLC
Researchers have uncovered a novel combination therapy leveraging the U.S. Food and Drug Administration (FDA)-approved KRAS inhibitor sotorasib and an experimental drug called FGTI-2734, which could improve the efficacy of precision medicine in patients with KRAS-mutated non–small cell lung cancer...
